RNTX
Rein Therapeutics, Inc.
$0.8650
-8.47%
$78.3M
No data for this timeframe.
Vol
Market Cap$78.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders11 funds
Inst. Value$1.8M
Inst. Activity0 buys / 1 sells
Insider Activity5B / 0S
Insider Net $$74.6K
SEC Reports5
Press Releases3
Recent Activity
Jun 8, 2026
SEC
Rein Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting of Stockh
DEFA14A — Impact 3/10
May 27, 2026
Insider
VON RICKENBACH JOSEF H bought 4,500 shares
Director @ $1.07 ($4.8K)
May 26, 2026
Insider
VON RICKENBACH JOSEF H bought 23,190 shares
Director @ $1.06 ($24.5K)
May 22, 2026
Insider
VON RICKENBACH JOSEF H bought 15,950 shares
Director @ $1.05 ($16.7K)
May 13, 2026
earnings_calendar
RNTX Q1 2026 Earnings Scheduled — 2026-05-13
May 4, 2026
SEC
Rein Therapeutics closed a massively dilutive underwritten public offering of 50M shares at $1.00 per share, raising ~$4
8-K — Impact 8/10
May 4, 2026
SEC
Rein Therapeutics is selling 50,000,000 shares (2.8x current outstanding) at $1.00 per share, a 26% discount to the last
424B5 — Impact 8/10
Inst.
HRT FINANCIAL LP — TRIM
15,486 shares ($20.00)
Price Targets
$8.00
+773.6% upside
Strong Buy
Current $0.9157
Low $8.00
Median $8.00
High $8.00
1 analysts
$8.00
$8.00
Analyst Ratings
2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 21, 2026 | Brookline Capital | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.27 ▲ +44.9% | $-0.27 — $-0.27 | 4% YoY | 1 |
| Next Q | $-0.10 ▲ +71.4% | $-0.10 — $-0.10 | 52% YoY | 1 |
| Current FY | $-0.53 ▲ +67.5% | $-0.53 — $-0.53 | 73% YoY | 1 |
| Next FY | $-0.50 ▲ +62.4% | $-0.50 — $-0.50 | 6% YoY | 1 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Rein Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting of Stockh
Jun 8, 2026
BEARISH
8-K
8/10
Rein Therapeutics closed a massively dilutive underwritten public offering of 50M shares at $1.00 per share, raising ~$4
May 4, 2026
BEARISH
Press
8/10
Rein Therapeutics priced a $50M underwritten public offering of 50M shares at $1.00/share, with an underwriter option fo
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.3M | — |
| VANGUARD FIDUCIARY TRUST CO | $200.9K | — |
| STATE STREET CORP | $98.7K | DOUBLED |
| BlackRock, Inc. | $89.1K | TRIM |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT | $55.2K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | VON RICKENBACH | BUY | $4.8K |
| May 26, 2026 | VON RICKENBACH | BUY | $24.5K |
| May 22, 2026 | VON RICKENBACH | BUY | $16.7K |
| May 21, 2026 | VON RICKENBACH | BUY | $3.6K |
| May 8, 2026 | WINDSOR JAMES | A | $0.00 |
11 institutional holders with $1.8M total value (1,407,782 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, STATE. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 998,521 | $1.3M | 71.7% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 154,512 | $200.9K | 11.1% | — |
| 3 | STATE STREET CORP | 75,904 | $98.7K | 5.5% | DOUBLED +374.3% |
| 4 | BlackRock, Inc. | 68,528 | $89.1K | 4.9% | TRIM -35.0% |
| 5 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 42,440 | $55.2K | 3.0% | — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 24,500 | $31.9K | 1.8% | — |
| 7 | Vanguard Global Advisers, LLC | 12,774 | $16.6K | 0.9% | — |
| 8 | HighTower Advisors, LLC | 10,000 | $13.0K | 0.7% | — |
| 9 | Rockefeller Capital Management L.P. | 5,097 | $6.6K | 0.4% | — |
| 10 | WELLS FARGO & COMPANY/MN | 20 | $26.00 | 0.0% | DOUBLED +84300.0% |
| 11 | HRT FINANCIAL LP | 15,486 | $20.00 | 0.0% | TRIM -53.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | TRIM | 33,237 | 15,486 | -53.4% | $20.00 | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 16,004 | 75,904 | +374.3% | $88.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 100 | 42 | -58.0% | $49.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 884,107 | 1,168,407 | +32.2% | $1.3M | 2025-Q3 |
| CITADEL ADVISORS LLC | TRIM | 47,994 | 28,201 | -41.2% | $32.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 262 | 100 | -61.8% | $115.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 15,701 | 83 | -99.5% | $95.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 2,980 | 15,701 | +426.9% | $22.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 2 | 1,688 | +84300.0% | $2.4K | 2025-Q2 |
| ROYAL BANK OF CANADA | TRIM | 106,972 | 57,257 | -46.5% | $101.0K | 2025-Q1 |
| BlackRock, Inc. | TRIM | 78,953 | 51,303 | -35.0% | $90.8K | 2025-Q1 |
| UBS Group AG | TRIM | 7,251 | 2,980 | -58.9% | $5.3K | 2025-Q1 |
| ROYAL BANK OF CANADA | DOUBLED | 8,000 | 106,972 | +1237.1% | $246.0K | 2024-Q4 |
| BlackRock, Inc. | ADD | 51,280 | 78,953 | +54.0% | $181.6K | 2024-Q4 |
| STATE STREET CORP | ADD | 10,404 | 16,004 | +53.8% | $36.8K | 2024-Q4 |
| ROYAL BANK OF CANADA | NEAR_EXIT | 60,241 | 8,000 | -86.7% | $28.0K | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 1,250 | 5,550 | +344.0% | $19.6K | 2024-Q3 |
2 unique insiders with 6 transactions. Net insider value: $74.6K ($74.6K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | VON RICKENBACH JOSEF H | Director | BUY | 4,500 | $1.07 | $4.8K |
| May 26, 2026 | VON RICKENBACH JOSEF H | Director | BUY | 23,190 | $1.06 | $24.5K |
| May 22, 2026 | VON RICKENBACH JOSEF H | Director | BUY | 15,950 | $1.05 | $16.7K |
| May 21, 2026 | VON RICKENBACH JOSEF H | Director | BUY | 3,420 | $1.04 | $3.6K |
| May 8, 2026 | WINDSOR JAMES BRIAN | See Remarks | AWARD | 150,000 | — | — |
| Apr 30, 2026 | WINDSOR JAMES BRIAN | See Remarks | BUY | 25,000 | $1.00 | $25.0K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 5.4/10.
NEUTRAL
DEFA14A
3/10
Rein Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annu
Jun 8, 2026
BEARISH
8-K
8/10
Rein Therapeutics closed a massively dilutive underwritten public offering of 50M shares at $1.00 pe
May 4, 2026
BEARISH
424B5
8/10
Rein Therapeutics is selling 50,000,000 shares (2.8x current outstanding) at $1.00 per share, a 26%
May 4, 2026
NEUTRAL
S-1
5/10
Rein Therapeutics, a clinical-stage biopharmaceutical company focused on orphan pulmonary and fibros
Apr 28, 2026
NEUTRAL
10-K/A
3/10
Rein Therapeutics filed an amended 10-K to include previously omitted Part III disclosures (Items 10
Apr 27, 2026
BEARISH
8/10
Rein Therapeutics priced a $50M underwritten public offering of 50M shares at $1.00/share, with an u
May 1, 2026
NEUTRAL
3/10
Rein Therapeutics provided a clinical update on its Phase 2 RENEW trial for LTI-03 in idiopathic pul
Apr 29, 2026
NEUTRAL
5/10
Rein Therapeutics has dosed the first patient in its Phase 2 clinical trial for LTI-03, an inhaled t
Mar 3, 2026
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 2 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.00 mean target
+773.6% upside
Strong Buy (3.00)
$8.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $0.9157 |
| Target Low | $8.00 |
| Target Mean | $8.00 |
| Target Median | $8.00 |
| Target High | $8.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.27 | $-0.27 | $-0.27 | 3.6% | +44.9% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.10 | $-0.10 | $-0.10 | 52.4% | +71.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.53 | $-0.53 | $-0.53 | 73.0% | +67.5% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.50 | $-0.50 | $-0.50 | 5.7% | +62.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.270 | |
| 7d ago | $-0.490 | +0.220 |
| 30d ago | $-0.490 | +0.220 |
| 60d ago | $0.000 | -0.270 |
| 90d ago | $0.000 | -0.270 |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | Brookline Capital | DOWNGRADE | Buy | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
RNTX Q1 2026 Earnings Scheduled — 2026-05-13
May 4, 2026
short_interest
FTD: RNTX — 854,528 shares ($0.9M) failed to deliver
Settlement: 20260504, Price: $1.03, FTD Value: $880,163.84, REIN THERAPEUTICS INC COM NEW
May 1, 2026
offering
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
<p align="justify">AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-st
Apr 29, 2026
fda
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
<p align="center"><strong>Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries</strong></p>
Apr 6, 2026
earnings_calendar
RNTX Q4 2025 Earnings After Market Close — 2026-04-06
Mar 3, 2026
fda
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for IPF